Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peptide Receptor Radionuclide Therapy”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Very early researchStudy completedNCT03647657
What this trial is testing

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

Who this might be right for
Thyroid Cancer, Medullary
University Hospital, Basel, Switzerland 8
Testing effectiveness (Phase 2)Temporarily pausedNCT05198479
What this trial is testing

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

Who this might be right for
Metastatic Nasopharyngeal Cancer
National Cancer Centre, Singapore 25
Testing effectiveness (Phase 2)Ended earlyNCT07012330
What this trial is testing

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Who this might be right for
Neuroendocrine (NE) Tumors
Erasmus Medical Center 111
Testing effectiveness (Phase 2)WithdrawnNCT04713202
What this trial is testing

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

Who this might be right for
Neuroendocrine TumorsCarcinoid SyndromeDiarrhea
Chandrikha Chandrasekhara
Testing effectiveness (Phase 2)UnknownNCT04029428
What this trial is testing

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 150
Early research (Phase 1)Active Not RecruitingNCT02088645
What this trial is testing

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

Who this might be right for
Thyroid Cancer, MedullaryNeuroendocrine Tumor of the Lung Grade 1 and 2Neuroendocrine Tumor of the Thymus Grade 1 and 2+1 more
University Hospital, Basel, Switzerland 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07434180
What this trial is testing

Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

Who this might be right for
Cancer of Unknown Primary
Peter MacCallum Cancer Centre, Australia 20
Not applicableUnknownNCT04622631
What this trial is testing

Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT

Who this might be right for
Neuroendocrine Tumors
Dr. Nayruz Knaana 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04261855
What this trial is testing

Targeted Therapy and Avelumab in Merkel Cell Carcinoma

Who this might be right for
Metastatic Merkel Cell Carcinoma
Melanoma and Skin Cancer Trials Limited 19
Testing effectiveness (Phase 2)Study completedNCT03936426
What this trial is testing

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Who this might be right for
Meningioma
Clarity Pharmaceuticals Ltd 5
Early research (Phase 1)Looking for participantsNCT05053854
What this trial is testing

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumors
Peter MacCallum Cancer Centre, Australia 24
Very early researchStudy completedNCT05871320
What this trial is testing

Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine Tumors
Jagiellonian University 10
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Early research (Phase 1)Study completedNCT03966651
What this trial is testing

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

Who this might be right for
Neuroblastoma
Institut Claudius Regaud 1
Testing effectiveness (Phase 2)Ended earlyNCT02489604
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 70
Early research (Phase 1)Active Not RecruitingNCT04609592
What this trial is testing

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Stanford University 10
Early research (Phase 1)Looking for participantsNCT05870423
What this trial is testing

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Who this might be right for
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Erasmus Medical Center 24
Not applicableStudy completedNCT00815620
What this trial is testing

Best Therapy for Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Zentralklinik Bad Berka 150
Testing effectiveness (Phase 2)Looking for participantsNCT06345079
What this trial is testing

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumors
Australasian Gastro-Intestinal Trials Group 78
Testing effectiveness (Phase 2)Study completedNCT03273712
What this trial is testing

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Who this might be right for
Neuroendocrine TumorsMeningiomaNeuroblastoma+1 more
University of Iowa 39
Next Page